SeaStar Medical Strengthens Board of Directors and Transitions to Commercial-Stage Company

Core Points - SeaStar Medical Holding Corporation has appointed three new members to its Board of Directors, enhancing its leadership team as it transitions to a commercial-stage company [1][2][3] - The new directors are Jennifer A. Baird, Bernadette N. Vincent, and John Neuman, who bring extensive experience in healthcare and finance [2][3][4] - The company expresses gratitude to departing directors Bruce Rodgers, Richard Russell, and Andres Lobo for their service [2] Company Overview - SeaStar Medical is a commercial-stage medical technology company focused on developing and commercializing cell-directed extracorporeal therapies aimed at reducing excessive inflammation in critically ill patients [5] - The company's innovative technologies are designed to target effector cells that drive systemic inflammation, which can lead to tissue damage and imbalanced immune responses [5]